Search

Nanotechnology, contrary to its name, has massively revolutionized industries around the world. This paper predominantly deals with data regarding the applications of nanotechnology in the modernization of several industries. A comprehensive research strategy is adopted to incorporate the latest data driven from major science platforms. Resultantly, a broad-spectrum overview is presented which comprises the diverse applications of nanotechnology in modern industries. This study reveals that nanotechnology is not limited to research labs or small-scale manufacturing units of nanomedicine, but instead has taken a major share in different industries. Companies around the world are now trying to make their innovations more efficient in terms of structuring, working, and designing outlook and productivity by taking advantage of nanotechnology. From small-scale manufacturing and processing units such as those in agriculture, food, and medicine industries to larger-scale production units such as those operating in industries of automobiles, civil engineering, and environmental management, nanotechnology has manifested the modernization of almost every industrial domain on a global scale. With pronounced cooperation among researchers, industrialists, scientists, technologists, environmentalists, and educationists, the more sustainable development of nano-based industries can be predicted in the future. [ABSTRACT FROM AUTHOR]

Quorum sensing (QS) regulates the expression of several genes including motility, biofilm development, virulence expression, population density detection and plasmid conjugation. It is based on "autoinducers", small molecules that microorganisms produce and release in the extracellular milieu. The biochemistry of quorum sensing is widely discussed and numerous papers are available to scientists. The main purpose of this research is to understand how knowledge about this mechanism can be exploited for the benefit of humans and the environment. Here, we report the most promising studies on QS and their resulting applications in different fields of global interest: food, agriculture and nanomedicine. [ABSTRACT FROM AUTHOR]

Background Participant selection for first-in-human (FIH) trials involves complex decisions. The trial design makes it unlikely that participants will receive clinically relevant therapeutic benefit, but they are likely to experience risks of various magnitudes and types. The aim of the present paper was to describe and discuss the views of investigators and ethics committee members about the choice of trial participants for FIH trials in cancer nanomedicine. Methods We drew insights from an exploratory qualitative study involving thematic analysis of 46 in-depth interviews with key stakeholders in Europe and North America involved in FIH nanomedicine trials. The present work draws on subset of 21 interviews with investigators and ethics committee members who have either conducted or reviewed a FIH cancer nanomedicine trial or are planning one. Results Investigators and ethics committee members are aware of the ethics standards for recruiting patients with end-stage cancer into FIH trials, but they nonetheless question the practice and provide reasons against it. Conclusions Although it is a standard and ethically accepted practice to enrol patients with end-stage cancer and no treatment options into FIH trials of investigational chemotherapeutic molecules, doing so can threaten the validity and generalizability of the trials, thereby weakening translational research. Another possibility is to stratify and include patients with less advanced disease who demonstrate certain biomarkers or cancer genotypes and who have a disease profile similar to that tested in preclinical studies. The latter approach could be a step toward personalized medical research and targeted drug development. Such a patient selection approach requires multi-stakeholder discussion to reach scientific and ethics consensus. [ABSTRACT FROM AUTHOR]

Simple Summary: In the past decades, the survival of ovarian malignant tumors has been largely unchanged. Treatment usually consists of a combination of systemic and surgical therapy. However, when recurrence occurs, treatment options are limited. When repeated surgery is no longer possible and chemotherapy is no longer effective, theranostics, a newly developing approach, might be of value. Theranostics will diagnose and destroy malignant tissue by binding radioactive isotopes to targets on malignant cells. To develop this approach, selection and validation of a target is necessary. For the selection of a target in ovarian tumors, the follicle-stimulating hormone (FSH) receptor appears to be suitable because it is primarily expressed in ovarian tissue, and expression is reported in malignant tumors. This review seeks to determine whether the follicle-stimulating hormone receptor is expressed in ovarian tumor types and, therefore, is suitable as a target in a future theranostic approach. Ovarian cancer mortality rates have not decreased significantly in the past years. As most women are still diagnosed in an advanced stage, there is a need for new treatment strategies for recurrent disease. A potentially new developing targeted approach, theranostics, combines diagnostics and treatment using radiopharmaceuticals. Through target receptors, imaging and treatment of malignant tissue can be achieved. For ovarian malignancy, the follicle-stimulating hormone (FSH) receptor may serve as a possible target since expression appears to be limited to ovarian cells. In this systematic review, we aim to gather all available literature on the expression of the FSH receptor in ovarian tumors. Pubmed, Embase and the Cochrane databases were searched until December 2023 for eligible studies. The search yielded 41 studies, mostly regarding serous carcinomas, sex cord–stromal tumors (SCSTs) and cell lines of serous and SCSTs. Various techniques were used to analyze the expression of the FSH receptor. For serous carcinomas, conflicting results on the expression of the FSH receptor were found. Studies on SCSTs, mainly studying the subtype of granulosa cell tumors, all showed positive expression of the FSH receptor. In the cell lines studies, the KGN cell line derived from a granulosa cell tumor shows positive expression in all studies. Available studies show that SCSTs express the FSH receptor. A theranostic approach targeting the FSH receptor may, therefore, provide a useful new approach for this malignancy with limited therapeutic options in recurrent disease. [ABSTRACT FROM AUTHOR]

Microwaves are non-ionizing electromagnetic radiation with waves of electrical and magnetic energy transmitted at different frequencies. They are widely used in various industries, including the food industry, telecommunications, weather forecasting, and in the field of medicine. Microwave applications in medicine are relatively a new field of growing interest, with a significant trend in healthcare research and development. The first application of microwaves in medicine dates to the 1980s in the treatment of cancer via ablation therapy; since then, their applications have been expanded. Significant advances have been made in reconstructing microwave data for imaging and sensing applications in the field of healthcare. Artificial intelligence (AI)-enabled microwave systems can be developed to augment healthcare, including clinical decision making, guiding treatment, and increasing resource-efficient facilities. An overview of recent developments in several areas of microwave applications in medicine, namely microwave imaging, dielectric spectroscopy for tissue classification, molecular diagnostics, telemetry, biohazard waste management, diagnostic pathology, biomedical sensor design, drug delivery, ablation treatment, and radiometry, are summarized. In this contribution, we outline the current literature regarding microwave applications and trends across the medical industry and how it sets a platform for creating AI-based microwave solutions for future advancements from both clinical and technical aspects to enhance patient care. [ABSTRACT FROM AUTHOR]

The human nature of curiosity, wonder, and ingenuity date back to the age of humankind. In parallel with our history of civilization, interest in scientific approaches to unravel mechanisms underlying natural phenomena has been developing. Recent years have witnessed unprecedented growth in research in the area of pharmaceuticals and medicine. The optimism that nanotechnology (NT) applied to medicine and drugs is taking serious steps to bring about significant advances in diagnosing, treating, and preventing disease—a shift from fantasy to reality. The growing interest in the future medical applications of NT leads to the emergence of a new field for nanomaterials (NMs) and biomedicine. In recent years, NMs have emerged as essential game players in modern medicine, with clinical applications ranging from contrast agents in imaging to carriers for drug and gene delivery into tumors. Indeed, there are instances where nanoparticles (NPs) enable analyses and therapies that cannot be performed otherwise. However, NPs also bring unique environmental and societal challenges, particularly concerning toxicity. Thus, clinical applications of NPs should be revisited, and a deep understanding of the effects of NPs from the pathophysiologic basis of a disease may bring more sophisticated diagnostic opportunities and yield more effective therapies and preventive features. Correspondingly, this review highlights the significant contributions of NPs to modern medicine and drug delivery systems. This study also attempted to glimpse the future impact of NT in medicine and pharmaceuticals. [ABSTRACT FROM AUTHOR]

The article discusses nanomedicine. Topics discussed include history of nanomedicine, tumor targeting drugs, several families of nanomaterials that have attracted increased attention as nanovectors and theranostics, and clinical trials of nanodrugs. Also discussed are the problems that most drugs are neither specific nor water-soluble.

Imagine devices or particles so small that they are invisible to the naked eye. Imagine that such entities could be used to patrol our bodies and autonomously augment endogenous defense and repair mechanisms. Imagine the defeat of illness at a fraction of the current costs. Bionanotechnology is the field of science that deals with just that: the development of imaging, tracking, targeting, sensing, diagnostic, and eventually therapeutic capabilities based on particles in the nanometer range, i.e., "nanoparticles". Within the extensive group of nanoparticles, semiconducting quantum dots play a central and prominent role. Quantum dots excel at a myriad of physical properties, most notably their fluorescent properties, such as high quantum yield, photo-stability, broad absorption spectra, and their remarkable size-dependent emission-tunability. [ABSTRACT FROM AUTHOR]

The use of fluorescent nanoparticles as probes for bioanalytical applications is a highly promising technique because fluorescence-based techniques are very sensitive. Quantum dots (QDs) seem to show the greatest promise as labels for tagging and imaging in biological systems owing to their impressive photostability, which allow long-term observations of biomolecules. The usage of QDs in practical applications has started only recently, therefore, the research on QDs is extremely important in order to provide safe and effective biosensing materials for medicine. This review reports on the recent methods for the preparation of quantum dots, their physical and chemical properties, surface modification as well as on some interesting examples of their experimental use. [ABSTRACT FROM AUTHOR]